BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1061 related articles for article (PubMed ID: 7922305)

  • 1. Tumor spectrum analysis in p53-mutant mice.
    Jacks T; Remington L; Williams BO; Schmitt EM; Halachmi S; Bronson RT; Weinberg RA
    Curr Biol; 1994 Jan; 4(1):1-7. PubMed ID: 7922305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of p53 transgenic mice in the development of cancer models for multiple purposes.
    Lubet RA; Zhang Z; Wiseman RW; You M
    Exp Lung Res; 2000 Dec; 26(8):581-93. PubMed ID: 11195457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
    Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
    Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.
    Venkatachalam S; Shi YP; Jones SN; Vogel H; Bradley A; Pinkel D; Donehower LA
    EMBO J; 1998 Aug; 17(16):4657-67. PubMed ID: 9707425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
    Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
    Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
    Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
    Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of genetic background on tumorigenesis in p53-deficient mice.
    Donehower LA; Harvey M; Vogel H; McArthur MJ; Montgomery CA; Park SH; Thompson T; Ford RJ; Bradley A
    Mol Carcinog; 1995 Sep; 14(1):16-22. PubMed ID: 7546219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
    Donehower LA; Harvey M; Slagle BL; McArthur MJ; Montgomery CA; Butel JS; Bradley A
    Nature; 1992 Mar; 356(6366):215-21. PubMed ID: 1552940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice.
    Backlund MG; Trasti SL; Backlund DC; Cressman VL; Godfrey V; Koller BH
    Cancer Res; 2001 Sep; 61(17):6577-82. PubMed ID: 11522657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.
    Kuperwasser C; Hurlbut GD; Kittrell FS; Dickinson ES; Laucirica R; Medina D; Naber SP; Jerry DJ
    Am J Pathol; 2000 Dec; 157(6):2151-9. PubMed ID: 11106587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice.
    Harvey M; Vogel H; Morris D; Bradley A; Bernstein A; Donehower LA
    Nat Genet; 1995 Mar; 9(3):305-11. PubMed ID: 7773294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 Testing for Li-Fraumeni and Li-Fraumeni-like syndromes.
    Gonzalez K; Fong C; Buzin C; Sommer SS; Saldivar JS
    Curr Protoc Hum Genet; 2008 Apr; Chapter 10():Unit 10.10. PubMed ID: 18428420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
    Stein T; Crighton D; Boyle JM; Varley JM; White RJ
    Oncogene; 2002 May; 21(19):2961-70. PubMed ID: 12082526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis.
    Srivastava S; Wang S; Tong YA; Hao ZM; Chang EH
    Cancer Res; 1993 Oct; 53(19):4452-5. PubMed ID: 8402611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
    Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
    Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.
    Tong WM; Hande MP; Lansdorp PM; Wang ZQ
    Mol Cell Biol; 2001 Jun; 21(12):4046-54. PubMed ID: 11359911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family.
    Stolzenberg MC; Brugières L; Gardes M; Dessarps-Freichey F; Chompret A; Bressac B; Lenoir G; Bonaïti-Pellié C; Lemerle J; Feunteun J
    Oncogene; 1994 Oct; 9(10):2799-804. PubMed ID: 8084585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse Homolog of the Human
    Park JH; Li J; Starost MF; Liu C; Zhuang J; Chen J; Achatz MI; Kang JG; Wang PY; Savage SA; Hwang PM
    Cancer Res; 2018 Sep; 78(18):5375-5383. PubMed ID: 30042151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational and LOH analyses of p53 alleles in colon tumors induced by 1,2-dimethylhydrazine in F1 hybrid mice.
    Okamoto M; Ohtsu H; Kominami R; Yonekawa H
    Carcinogenesis; 1995 Nov; 16(11):2659-66. PubMed ID: 7586183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity.
    Biggs PJ; Vogel H; Sage M; Martin LA; Donehower LA; Bradley A
    Oncogene; 2003 May; 22(21):3288-96. PubMed ID: 12761499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.